Acta Ophthalmol
Acta OphthalmolDecember 2021Journal Article

Risk of ocular hypertension in children treated with systemic glucocorticoid.

IOP & Medical TherapyDiagnosis & Screening

Summary

Systemic treatment of children with glucocorticoid can cause a significant increase in IOP which indicates the need for IOP screening of these children.

Abstract

PURPOSE

To investigate the risk of steroid-induced ocular hypertension in children treated with systemic glucocorticoid.

METHODS

Prospective cohort study of children treated with high-dose systemic glucocorticoid (prednisolone-equivalent >0.5 mg/kg/day) for more than 2 weeks. Intraocular pressure (IOP) was measured by an Icare tonometer. An intraocular hypertensive response was defined as a net increase in IOP ≥6 mmHg from baseline or a peak IOP ≥21 mmHg in either eye. Patients with a peak IOP ≥31 mmHg or a net increase in IOP ≥15 mmHg were considered as high responders.

RESULTS

Sixteen children with median age 12 years (range 5-17) were included in the study. Nine children (56%) developed a steroid-induced ocular hypertensive response. Two children (12%) were high responders with peak IOP between 32 and 44 mmHg and a net increase in IOP between 15 and 23 mmHg. All children were asymptomatic and IOP was normalized in all after withdrawal of steroid. Steroid responders were significantly younger than nonresponders (p = 0.03). No associations were found between net IOP increase and time to peak pressure, steroid dose at peak pressure or accumulated prednisolone dose at peak IOP.

CONCLUSION

Systemic treatment of children with glucocorticoid can cause a significant increase in IOP which indicates the need for IOP screening of these children. The risk of steroid-induced ocular hypertension may depend on age and ethnicity. In this perspective, further studies on Caucasian children are needed.

Keywords

childrenglaucomaocular hypertensionscreeningsteroid

Discussion

Comments and discussion will appear here in a future update.